Cornell’s participation in the U.S. Commerce Department initiative will help advance development and deployment of safe and trustworthy artificial intelligence technology.
A multicenter, phase 3 clinical trial has found that apixaban is no more effective than aspirin at preventing a second stroke in patients diagnosed with a milder, related condition called atrial cardiopathy, according to new research.
Alessio Accardi, professor of physiology and biophysics in anesthesiology at Weill Cornell Medicine, has been awarded a five-year, $2.7 million grant for fundamental research on cell membrane proteins that have critical roles in biology and are involved in numerous human diseases.
Jeannine Gerhardt, an assistant professor of stem cell biology in obstetrics and gynecology and in reproductive medicine at Weill Cornell Medicine, has received a five-year, $2.1 million grant for the study of repetitive DNA and RNA sequences and the mechanisms by which they cause cell dysfunction and diseases.
The university has announced a realignment within the Office of the Executive Vice President and Chief Financial Officer designed to improve long-term financial oversight and cross-campus coordination between Ithaca and Weill Cornell Medicine in New York City.
Structural insights into a potent antimalarial drug candidate’s interaction with a malaria parasite have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.
Non-cancerous cells called stromal cells, which are found in and around prostate tumors, may be useful in assessing these tumors’ potential to spread, and may even be targets for future prostate cancer treatments, according to a study led by researchers at Weill Cornell Medicine.
